Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and operated territories, independent contractor-operated territories, and franchised locations. This segment also manufactures and sells products and equipment, including drain cleaning machines and drain cleaning solutions. The company was founded in 1970 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:CHE
CUSIP16359R10
Phone513-762-6690
Debt
Debt-to-Equity Ratio0.17%
Current Ratio0.91%
Quick Ratio0.88%
Price-To-Earnings
Trailing P/E Ratio31.03
Forward P/E Ratio28.25
P/E Growth2.83
Sales & Book Value
Annual Sales$1.67 billion
Price / Sales2.94
Cash Flow$7.9697 per share
Price / Cash38.00
Book Value$33.84 per share
Price / Book8.95
Profitability
EPS (Most Recent Fiscal Year)$5.36
Net Income$98.17 million
Net Margins6.67%
Return on Equity33.33%
Return on Assets17.99%
Miscellaneous
Employees14,813
Outstanding Shares16,160,000
Chemed (NYSE:CHE) Frequently Asked Questions
What is Chemed's stock symbol?
Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."
How often does Chemed pay dividends? What is the dividend yield for Chemed?
Chemed declared a quarterly dividend on Friday, February 16th. Shareholders of record on Monday, February 26th will be given a dividend of $0.28 per share on Monday, March 19th. This represents a $1.12 annualized dividend and a yield of 0.37%. The ex-dividend date is Friday, February 23rd. View Chemed's Dividend History.
How will Chemed's stock buyback program work?
Chemed declared that its board has approved a stock repurchase program on Wednesday, March 7th 2018, which authorizes the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's board believes its shares are undervalued.
How were Chemed's earnings last quarter?
Chemed Corp. (NYSE:CHE) announced its quarterly earnings results on Thursday, April, 19th. The company reported $2.72 EPS for the quarter, topping the consensus estimate of $2.36 by $0.36. The firm had revenue of $439.18 million for the quarter, compared to analyst estimates of $419.33 million. Chemed had a net margin of 6.67% and a return on equity of 33.33%. The firm's revenue was up 8.2% compared to the same quarter last year. During the same period last year, the business posted $1.82 earnings per share. View Chemed's Earnings History.
When is Chemed's next earnings date?
What guidance has Chemed issued on next quarter's earnings?
Chemed updated its FY18 earnings guidance on Thursday, April, 19th. The company provided EPS guidance of $10.60-10.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.72.
What price target have analysts set for CHE?
3 analysts have issued twelve-month target prices for Chemed's shares. Their predictions range from $258.00 to $275.00. On average, they expect Chemed's share price to reach $266.50 in the next twelve months. View Analyst Ratings for Chemed.
Who are some of Chemed's key competitors?
Some companies that are related to Chemed include Alnylam Pharmaceuticals (ALNY), Eurofins Scientific (ERFSF), Jazz Pharmaceuticals (JAZZ), BioMérieux (BMXMF), BeiGene (BGNE), WellCare (WCG), bluebird bio (BLUE), STERIS (STE), Seattle Genetics (SGEN), Bio-Rad Laboratories (BIO), Valeant Pharmaceuticals International (VRX), AveXis (AVXS), Neurocrine Biosciences (NBIX), Alkermes (ALKS), SAGE Therapeutics (SAGE), West Pharmaceutical Services (WST), Stada Arzneimittel (STDAF) and ICON (ICLR).
Who are Chemed's key executives?
Chemed's management team includes the folowing people:
- Mr. Kevin J. McNamara, Pres, CEO & Director (Age 64)
- Mr. David P. Williams, Exec. VP & CFO (Age 57)
- Mr. Spencer S. Lee, Exec. VP (Age 62)
- Mr. Nicholas Michael Westfall, Exec. VP (Age 39)
- Mr. Timothy S. O'Toole, Consultant (Age 62)
Has Chemed been receiving favorable news coverage?
Press coverage about CHE stock has trended somewhat negative recently, Accern reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chemed earned a media sentiment score of -0.02 on Accern's scale. They also gave headlines about the company an impact score of 46.38 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Chemed's major shareholders?
Chemed's stock is owned by many different of retail and institutional investors. Top institutional investors include
GAMCO INVESTORS, INC. ET AL
(4.28%). Company insiders that own Chemed stock include Arthur V Tucker Jr, David Patrick Williams, Donald E Saunders, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace and Spencer S Lee. View Institutional Ownership Trends for Chemed.
How do I buy shares of Chemed?
Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chemed's stock price today?
One share of CHE stock can currently be purchased for approximately $302.85.
How big of a company is Chemed?
Chemed has a market capitalization of $4.89 billion and generates $1.67 billion in revenue each year. The company earns $98.17 million in net income (profit) each year or $5.36 on an earnings per share basis. Chemed employs 14,813 workers across the globe.
How can I contact Chemed?
Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.
MarketBeat Community Rating for Chemed (CHE)
MarketBeat's community ratings are surveys of what our community members think about Chemed and other stocks. Vote "Outperform" if you believe CHE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Chemed (NYSE:CHE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Chemed in the last 12 months. Their average twelve-month price target is $266.50, suggesting that the stock has a possible downside of 12.00%. The high price target for CHE is $275.00 and the low price target for CHE is $258.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.33 | 2.33 | 2.33 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $266.50 | $266.50 | $228.50 | $214.50 |
| Price Target Upside: | 12.00% downside | 4.40% upside | 2.63% upside | 5.41% upside |
Chemed (NYSE:CHE) Consensus Price Target History
Chemed (NYSE:CHE) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Chemed (NYSE:CHE) Dividend Information
Chemed pays an annual dividend of $1.12 per share, with a dividend yield of 0.37%. CHE's most recent quarterly dividend payment was Monday, March 19. The company has grown its dividend for the last 9 consecutive years and is increasing its dividend by an average of 8.70% each year. Chemed pays out 20.90% of its earnings out as a dividend.
| Most Recent Dividend: | 3/19/2018 |
| Annual Dividend: | $1.12 |
| Dividend Yield: | 0.37% |
| Dividend Growth: | 8.70% (3 Year Average) |
| Payout Ratio: | 20.90% (Trailing 12 Months of Earnings)
10.45% (Based on This Year's Estimates)
9.85% (Based on Next Year's Estimates)
|
| Track Record: | 9 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Chemed (NYSE:CHE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/16/2018 | quarterly | $0.28 | 0.41% | 2/23/2018 | 2/26/2018 | 3/19/2018 |
| 11/3/2017 | Quarterly | $0.28 | 0.48% | 11/10/2017 | 11/13/2017 | 12/4/2017 |
| 9/22/2017 | Monthly | $0.10 | | 9/28/2017 | 9/29/2017 | 10/31/2017 |
| 8/23/2017 | Monthly | $0.10 | | 8/29/2017 | 8/31/2017 | 9/29/2017 |
| 8/4/2017 | quarterly | $0.28 | 0.57% | 8/10/2017 | 8/14/2017 | 9/1/2017 |
| 7/21/2017 | Monthly | $0.10 | | 7/27/2017 | 7/31/2017 | 8/31/2017 |
| 6/22/2017 | Monthly | $0.10 | | 6/28/2017 | 6/30/2017 | 7/31/2017 |
| 5/15/2017 | Quarterly | $0.26 | 0.51% | 5/23/2017 | 5/25/2017 | 6/14/2017 |
| 2/17/2017 | quarterly | $0.26 | 0.59% | 2/23/2017 | 2/27/2017 | 3/20/2017 |
| 11/4/2016 | quarterly | $0.26 | 0.76% | 11/9/2016 | 11/14/2016 | 12/5/2016 |
| 8/5/2016 | quarterly | $0.26 | 0.72% | 8/11/2016 | 8/15/2016 | 9/2/2016 |
| 5/16/2016 | quarterly | $0.24 | 0.76% | 5/24/2016 | 5/26/2016 | 6/15/2016 |
| 2/19/2016 | quarterly | $0.24 | 0.75% | 2/25/2016 | 2/29/2016 | 3/21/2016 |
| 11/6/2015 | quarterly | $0.24 | 0.63% | 11/12/2015 | 11/16/2015 | 12/7/2015 |
| 8/7/2015 | quarterly | $0.24 | 0.63% | 8/13/2015 | 8/17/2015 | 9/4/2015 |
| 5/18/2015 | quarterly | $0.22 | 0.71% | 5/26/2015 | 5/28/2015 | 6/17/2015 |
| 2/20/2015 | quarterly | $0.22 | 0.77% | 2/26/2015 | 3/2/2015 | 3/23/2015 |
| 11/7/2014 | quarterly | $0.22 | 0.81% | 11/13/2014 | 11/17/2014 | 12/8/2014 |
| 8/11/2014 | quarterly | $0.22 | 0.88% | 8/14/2014 | 8/18/2014 | 9/13/2014 |
| 8/8/2014 | quarterly | $0.22 | | 8/14/2014 | 8/18/2014 | 9/3/2014 |
| 5/19/2014 | quarterly | $0.20 | 0.91% | 5/27/2014 | 5/29/2014 | 6/18/2014 |
| 2/21/2014 | quarterly | $0.20 | 0.94% | 2/27/2014 | 3/3/2014 | 3/24/2014 |
| 11/8/2013 | quarterly | $0.20 | 1.13% | 11/14/2013 | 11/18/2013 | 12/9/2013 |
| 8/2/2013 | quarterly | $0.20 | 1.1% | 8/8/2013 | 8/12/2013 | 9/3/2013 |
| 5/20/2013 | quarterly | $0.18 | 1.05% | 5/28/2013 | 5/30/2013 | 6/19/2013 |
| 2/20/2013 | quarterly | $0.18 | 0.92% | 2/28/2013 | 3/4/2013 | 3/22/2013 |
(Data available from 1/1/2013 forward)
Chemed (NYSE CHE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 94.78%
Chemed (NYSE CHE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | Kevin J Mcnamara | Insider | Sell | 6,000 | $258.00 | $1,548,000.00 | 140,049 |  |
| 2/21/2018 | Naomi C Dallob | VP | Sell | 1,050 | $257.00 | $269,850.00 | 6,649 | |
| 12/4/2017 | Michael D Witzeman | VP | Sell | 1,000 | $250.00 | $250,000.00 | 3,334 | |
| 11/29/2017 | David Patrick Williams | Insider | Sell | 11,000 | $241.28 | $2,654,080.00 | 74,857 | |
| 11/27/2017 | Naomi C Dallob | VP | Sell | 950 | $240.38 | $228,361.00 | 9,747 | |
| 11/22/2017 | Spencer S Lee | Insider | Sell | 1,000 | $238.24 | $238,240.00 | 34,809 | |
| 11/16/2017 | Michael D Witzeman | VP | Sell | 1,579 | $235.00 | $371,065.00 | 4,334 | |
| 11/15/2017 | Kevin J Mcnamara | CEO | Sell | 5,000 | $232.59 | $1,162,950.00 | 136,800 | |
| 11/15/2017 | Spencer S Lee | Insider | Sell | 1,000 | $232.27 | $232,270.00 | 35,809 | |
| 11/13/2017 | Nicholas Michael Westfall | Insider | Sell | 10,000 | $231.00 | $2,310,000.00 | 13,351 | |
| 11/8/2017 | Naomi C Dallob | VP | Sell | 1,900 | $231.00 | $438,900.00 | 10,426 | |
| 11/2/2017 | Donald E Saunders | Director | Sell | 500 | $227.75 | $113,875.00 | 10,298 | |
| 11/2/2017 | Spencer S Lee | EVP | Sell | 1,000 | $228.45 | $228,450.00 | 36,809 | |
| 10/31/2017 | Kevin J Mcnamara | CEO | Sell | 10,000 | $223.42 | $2,234,200.00 | 170,016 | |
| 10/31/2017 | Naomi C Dallob | VP | Sell | 750 | $222.09 | $166,567.50 | 9,097 | |
| 10/2/2017 | Patrick P Grace | Director | Sell | 500 | $201.48 | $100,740.00 | 4,515 | |
| 9/1/2017 | Spencer S Lee | Insider | Sell | 1,000 | $197.46 | $197,460.00 | 37,809 | |
| 7/28/2017 | Kevin J Mcnamara | Insider | Sell | 15,000 | $201.16 | $3,017,400.00 | 173,801 | |
| 6/26/2017 | George J Walsh III | Director | Buy | 1,000 | $204.56 | $204,560.00 | 7,908 | |
| 5/4/2017 | Donald E Saunders | Director | Buy | 94 | $205.59 | $19,325.46 | 9,886 | |
| 5/3/2017 | Donald E Saunders | Director | Sell | 400 | $204.85 | $81,940.00 | 9,886 | |
| 5/2/2017 | Kevin J Mcnamara | Insider | Sell | 4,000 | $205.11 | $820,440.00 | 148,943 | |
| 5/1/2017 | Spencer S Lee | Insider | Sell | 1,000 | $202.47 | $202,470.00 | 39,147 | |
| 3/3/2017 | Kevin J Mcnamara | Insider | Sell | 7,000 | $181.74 | $1,272,180.00 | 149,191 | |
| 3/2/2017 | Arthur V Tucker Jr | VP | Sell | 2,266 | $181.00 | $410,146.00 | 1,800 | |
| 2/27/2017 | Arthur V Tucker Jr | VP | Sell | 8,878 | $179.21 | $1,591,026.38 | 8,070 | |
| 2/24/2017 | Kevin J Mcnamara | Insider | Sell | 7,000 | $177.63 | $1,243,410.00 | 160,010 | |
| 11/28/2016 | Patrick P Grace | Director | Sell | 400 | $148.53 | $59,412.00 | 4,597 | |
| 11/14/2016 | Donald E Saunders | Director | Sell | 500 | $149.56 | $74,780.00 | 10,286 | |
| 11/14/2016 | Spencer S Lee | Insider | Sell | 4,500 | $150.22 | $675,990.00 | 35,367 | |
| 10/31/2016 | Kevin J Mcnamara | Insider | Sell | 10,000 | $138.40 | $1,384,000.00 | 189,266 | |
| 9/22/2016 | Spencer S Lee | Insider | Sell | 2,000 | $141.67 | $283,340.00 | 39,867 | |
| 8/8/2016 | Donald E Saunders | Director | Sell | 500 | $144.32 | $72,160.00 | 10,786 | |
| 8/5/2016 | Arthur V Tucker Jr | VP | Sell | 4,500 | $144.28 | $649,260.00 | 7,734 | |
| 8/4/2016 | Arthur V Tucker Jr | VP | Sell | 3,089 | $143.88 | $444,445.32 | 3,234 | |
| 8/3/2016 | Kevin J Mcnamara | Insider | Sell | 18,000 | $144.87 | $2,607,660.00 | 163,266 | |
| 5/16/2016 | Donald E Saunders | Director | Buy | 77 | $126.53 | $9,742.81 | 11,209 | |
| 3/21/2016 | Spencer S Lee | EVP | Sell | 24,382 | $132.29 | $3,225,494.78 | 62,087 | |
| 1/27/2016 | Patrick P Grace | Director | Sell | 50 | $138.98 | $6,949.00 | 4,522 | |
| 12/11/2015 | David Patrick Williams | CFO | Sell | 5,000 | $151.72 | $758,600.00 | 36,968 | |
| 11/24/2015 | Spencer S Lee | EVP | Sell | 5,000 | $154.10 | $770,500.00 | 43,405 | |
| 11/6/2015 | Kevin J Mcnamara | CEO | Sell | 6,000 | $157.02 | $942,120.00 | 167,736 | |
| 10/27/2015 | Spencer S. Lee | EVP | Sell | 4,000 | $153.64 | $614,560.00 | 48,405 | |
| 10/26/2015 | Kevin J. Mcnamara | CEO | Sell | 8,000 | $149.04 | $1,192,320.00 | 173,736 | |
| 8/24/2015 | David Patrick Williams | CFO | Sell | 10,000 | $138.09 | $1,380,900.00 | 29,268 | |
| 5/15/2015 | Arthur V Tucker Jr | VP | Sell | 9,000 | $121.00 | $1,089,000.00 | | |
| 5/7/2015 | Kevin J Mcnamara | CEO | Sell | 8,000 | $120.82 | $966,560.00 | | |
| 3/6/2015 | Spencer S Lee | EVP | Sell | 9,931 | $115.16 | $1,143,653.96 | | |
| 3/2/2015 | Timothy S Otoole | EVP | Sell | 10,000 | $117.82 | $1,178,200.00 | | |
| 2/27/2015 | Arthur V Tucker Jr | VP | Sell | 7,000 | $116.80 | $817,600.00 | | |
| 2/24/2015 | Arthur V Tucker Jr | VP | Sell | 2,685 | $114.35 | $307,029.75 | | |
| 2/23/2015 | Spencer S Lee | EVP | Sell | 10,000 | $113.18 | $1,131,800.00 | | |
| 2/20/2015 | Kevin J Mcnamara | CEO | Sell | 13,000 | $112.71 | $1,465,230.00 | | |
| 11/14/2014 | Timothy S Otoole | EVP | Sell | 5,000 | $106.81 | $534,050.00 | | |
| 11/13/2014 | Spencer S Lee | EVP | Sell | 10,000 | $108.38 | $1,083,800.00 | | |
| 11/4/2014 | Kevin J Mcnamara | CEO | Sell | 4,000 | $104.13 | $416,520.00 | | |
| 9/10/2014 | Spencer S Lee | EVP | Sell | 2,000 | $105.80 | $211,600.00 | | |
| 9/8/2014 | David Patrick Williams | CFO | Sell | 5,000 | $105.90 | $529,500.00 | | |
| 8/7/2014 | Kevin J Mcnamara | CEO | Sell | 5,000 | $100.05 | $500,250.00 | | |
| 7/25/2014 | Arthur V Tucker Jr | VP | Sell | 9,000 | $101.26 | $911,340.00 | | |
| 7/25/2014 | Kevin J Mcnamara | CEO | Sell | 10,000 | $101.00 | $1,010,000.00 | | |
| 5/15/2014 | Timothy Otoole | EVP | Sell | 9,000 | $87.62 | $788,580.00 | 31,170 | |
| 5/5/2014 | Kevin Mcnamara | CEO | Sell | 5,000 | $85.05 | $425,250.00 | 178,710 | |
| 4/2/2014 | Spencer Lee | EVP | Sell | 2,000 | $90.15 | $180,300.00 | 65,848 | |
| 3/19/2014 | Thomas Hutton | VP | Sell | 2,201 | $88.36 | $194,480.36 | 28,699 | |
| 3/11/2014 | Timothy Otoole | EVP | Sell | 6,000 | $86.60 | $519,600.00 | 37,519 | |
| 3/3/2014 | Kevin Mcnamara | CEO | Sell | 4,000 | $84.47 | $337,880.00 | 178,616 | |
| 2/28/2014 | Arthur Tucker, Jr. | VP | Sell | 9,000 | $85.01 | $765,090.00 | 8,282 | |
| 2/25/2014 | Arthur Tucker, Jr. | VP | Sell | 8,461 | $83.80 | $709,031.80 | 8,282 | |
| 2/20/2014 | Spencer Lee | EVP | Sell | 2,000 | $82.51 | $165,020.00 | 67,848 | |
| 2/19/2014 | Kevin Mcnamara | CEO | Sell | 4,000 | $82.18 | $328,720.00 | 182,616 | |
(Data available from 1/1/2013 forward)
Chemed (NYSE CHE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Chemed's (CHE) CEO Kevin McNamara on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 20 at 5:01 PM |
 | Chemed Corporation (CHE) Tops Q1 EPS by 36c, Maintains Guidance
www.streetinsider.com - April 20 at 8:53 AM |
 | Chemed (CHE) Beats on Q1 Earnings & Revenues, Retains View
www.msn.com - April 20 at 8:53 AM |
 | Chemed (CHE) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS
www.americanbankingnews.com - April 19 at 6:56 PM |
| Chemed beats by $0.36, beats on revenue
seekingalpha.com - April 19 at 5:14 PM |
| Chemed Q1 top line up 8%; earnings up 51%
seekingalpha.com - April 19 at 5:14 PM |
 | BRIEF-Chemed Corp Q1 GAAP Earnings Per Share $2.66
www.reuters.com - April 19 at 5:14 PM |
 | Chemed: 1Q Earnings Snapshot
finance.yahoo.com - April 19 at 5:14 PM |
| Chemed Reports First-Quarter 2018 Results
finance.yahoo.com - April 19 at 5:14 PM |
| Chemed (CHE) Releases FY18 Earnings Guidance
www.americanbankingnews.com - April 19 at 5:08 PM |
| VITAS HEALTHCARE BRINGS EXPERTISE IN RISK MITIGATION AND VALUE-BASED CARE TO APG CONFERENCE IN SAN DIEGO
finance.yahoo.com - April 18 at 4:57 PM |
| Chemed (CHE) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 14 at 8:30 AM |
| Chemed (CHE) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 12 at 1:25 AM |
| Form DEF 14A CHEMED CORP For: May 21
www.streetinsider.com - April 11 at 4:57 PM |
| VITAS HEALTHCARE REFERRALS MADE EASIER WITH HOSPICE APP’S FACE SHEET
finance.yahoo.com - April 9 at 5:05 PM |
| Chemed (CHE) Stock Rating Reaffirmed by Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM |
| Chemed (CHE) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 3 at 5:52 PM |
| Chemed (CHE) Rating Increased to A- at TheStreet
www.americanbankingnews.com - April 2 at 9:42 PM |
| Royal Bank of Canada Boosts Chemed (CHE) Price Target to $232.00
www.americanbankingnews.com - April 2 at 8:04 PM |
| Chemed Co. (CHE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 2 at 1:46 AM |
| LHC Group (LHCG) & Chemed (CHE) Critical Review
www.americanbankingnews.com - April 1 at 1:36 AM |
| Critical Comparison: Chemed (CHE) versus BioTelemetry (BEAT)
www.americanbankingnews.com - March 18 at 1:04 AM |
| Chemed Corporation to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 4:58 PM |
| Chemed Co. (CHE) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 8 at 1:24 AM |
| Chemed (CHE) Declares Share Buyback Plan
www.americanbankingnews.com - March 7 at 11:49 AM |
| Chemed Corporation’s Board of Directors Authorizes an Additional $150 Million for Stock Repurchase
finance.yahoo.com - March 6 at 4:54 PM |
| Chemed Co. (CHE) Stake Decreased by Formidable Asset Management LLC
www.americanbankingnews.com - March 6 at 9:50 AM |
| Chemed Co. (CHE) Shares Sold by Schroder Investment Management Group
www.americanbankingnews.com - March 6 at 9:48 AM |
| 26,005 Shares in Chemed Co. (CHE) Purchased by WINTON GROUP Ltd
www.americanbankingnews.com - March 5 at 4:09 PM |
| State of Tennessee Treasury Department Decreases Position in Chemed Co. (CHE)
www.americanbankingnews.com - March 5 at 3:28 PM |
| Chemed Co. (CHE) Insider Sells $1,548,000.00 in Stock
www.americanbankingnews.com - March 2 at 3:54 PM |
| Investec Asset Management LTD Sells 27,574 Shares of Chemed Co. (CHE)
www.americanbankingnews.com - March 2 at 3:47 PM |
| Chemed Co. (CHE) Holdings Trimmed by Royce & Associates LP
www.americanbankingnews.com - March 2 at 10:44 AM |
| Fuller & Thaler Asset Management Inc. Acquires 8,600 Shares of Chemed Co. (CHE)
www.americanbankingnews.com - March 1 at 10:50 AM |
| Sei Investments Co. Buys 9,473 Shares of Chemed Co. (CHE)
www.americanbankingnews.com - March 1 at 9:22 AM |
| Chemed Co. (CHE) Shares Bought by BlackRock Inc.
www.americanbankingnews.com - March 1 at 5:08 AM |
| Teacher Retirement System of Texas Sells 247 Shares of Chemed Co. (CHE)
www.americanbankingnews.com - February 28 at 5:07 PM |
| Chemed Co. (CHE) Shares Bought by Rhumbline Advisers
www.americanbankingnews.com - February 28 at 7:52 AM |
| Chemed Co. (CHE) Holdings Lowered by Systematic Financial Management LP
www.americanbankingnews.com - February 27 at 11:28 AM |
| Chemed Corp (CHE) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 26 at 4:57 PM |
| Chemed Co. (CHE) Shares Sold by Martingale Asset Management L P
www.americanbankingnews.com - February 26 at 2:41 PM |
| Eaton Vance Management Invests $19.97 Million in Chemed Co. (CHE)
www.americanbankingnews.com - February 26 at 2:38 PM |
| Chemed Co. (CHE) Shares Sold by Smith Asset Management Group LP
www.americanbankingnews.com - February 25 at 2:28 PM |
| California Public Employees Retirement System Sells 307 Shares of Chemed Co. (CHE)
www.americanbankingnews.com - February 24 at 5:12 AM |
| Chemed Co. (CHE) VP Naomi C. Dallob Sells 1,050 Shares
www.americanbankingnews.com - February 21 at 12:31 PM |
| Chemed Co. (CHE) to Issue $0.28 Quarterly Dividend
www.americanbankingnews.com - February 16 at 2:36 PM |
| Chemed (CHE) Receives "Hold" Rating from Royal Bank of Canada
www.americanbankingnews.com - February 16 at 11:24 AM |
| Oppenheimer Increases Chemed (CHE) Price Target to $275.00
www.americanbankingnews.com - February 16 at 11:24 AM |
| Chemed Corporation to Present at the 2018 RBC Capital Markets’ Global Healthcare Conference
finance.yahoo.com - February 15 at 5:06 PM |
| Chemed Reports Fourth-Quarter 2017 Results
finance.yahoo.com - February 15 at 6:58 AM |
Chemed (NYSE:CHE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Chemed (NYSE:CHE) Income Statement, Balance Sheet and Cash Flow Statement
Chemed (NYSE CHE) Stock Chart for Sunday, April, 22, 2018
Loading chart…
